Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC)
Biodesix provided an update on the Observational Registry study to evaluate the impact of BDX-XL2 on physician decision making in routine clinical use (ORACLE)
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
Biodesix presented positive data for a blood-based test with the potential to detect a non-small cell lung cancer (NSCLC) patient’s pre-treatment risk of anti-PD-1 immunotherapy resistance
Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules in New CHEST Data Publication
Biodesix announced newly published data showing the noninvasive BDX-XL2 test could reduce the number of unnecessary biopsies carried out on patients with benign nodules
Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
A new study published in the Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer
Biodesix announced that it has acquired Integrated Diagnostics, Inc.
Society for Advanced Bronchoscopy Commits to Enhance Education and Practice Excellence as U.S. Demand for Bronchoscopy Procedures Increases
Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care for Americans
The Society for Advanced Bronchoscopy (SAB) will hold its second meeting: Hot Topics in Advanced Bronchoscopy.
New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions
New data demonstrate that a blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions.
Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex